Skip to main navigationSkip to main content
The University of Southampton
Southampton Clinical Trials Unit

Anti CD66 Trial

Trial Name

Anti-CD66 - A randomised Phase II Clinical Trial using Targeted Radiotherapy delivered by an Yttrium-90 Radio-labelled Anti-CD66 Monoclonal Antibody with high dose melphalan compared to melphalan alone, prior to Autologous Stem Cell Transplantation for Multiple Myeloma. 

Description

A randomised phase II trial comparing two transplant conditioning schedules prior to autologous stem cell transplantation in patients with multiple myeloma.

Objectives

Primary Objective:

Secondary Ojective:

Design

A randomised, non-blind Phase II study with two treatment arms comparing two transplant conditioning schedules prior to autologous stem cell rescue:

Status

Complete

Population

80 Patients with multiple myeloma scheduled for autologous stem cell transplantation recruited from three treatment centres and randomised in a 1:1 fashion.

Contact details

All Trial enquiries should be addressed to ctu@soton.ac.uk

Privacy Settings